Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects

American Journal of Cardiology

Volumn 90, Issue 7, 2002, Pages 689-696

  Schaefer, Ernst J ^a,c   McNamara, Judith R ^a   Tayler, Timothy ^a   Daly, Jennifer A ^a   Gleason, Joi A ^a   Seman, Leo J ^a   Ferrari, Andrea ^b   Rubenstein, Joel J ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEWTON WELLESLEY HOSPITAL   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0036803259     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02591-2     Document Type: Article

References (30)

1. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 166:1987;1-8.
2. Jenner J.L., Ordovas J.M., Lamon-Fava S., Schaefer M.M., Wilson P.W., Castelli W.P., Schaefer E.J. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 87:1993;1135-1141.
3. Seman L.J., Jenner J.L., McNamara J.R., Schaefer E.J. Quantitation of plasma lipoprotein (a) by cholesterol assay of lectin-bound lipoprotein (a). Clin Chem. 40:1994;400-403.
4. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I as determined with a commercially available immunoturbidometric assay: Results from the Framingham Offspring Study. Clin Chem 1996;42:507-514.
5. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Schaefer EJ. Reference intervals for plasma apolipoprotein B as determined with a commercially available immunoturbidometric assay: Results from the Framingham Offspring Study. Clin Chem 1996;42:515-523.
6. Campos E., Nakajima K., Tanaka A., Havel R.J. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 33:1992;369-380.
7. Nakajima K., Saito T., Tamura A., Suzuki M., Nakano T., Adachi M., Tanaka A., Tada N., Nakamura H., Campos E., Havel R.J. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 223:1993;53-71.
8. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W.F., Ordovas J.M., Schaefer E.J. Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study . Clin Chem. 44:1998;1224-1232.
9. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 38:1992;1632-1638.
10. Couture P, Otvos JD, Cupples LA, Wilson PW, Schaefer EJ, Ordovas JM. Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res 1999;40:1883-1889.
11. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18B-25B.
12. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-1419.
13. Schaefer E.J., Audelin M.C., McNamara J.R., Shah P.K., Tayler T., Daly J.A., Augustin J.L., Seman L.J., Rubenstein J.J. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol. 88:2001;1129-1133.
14. Kugiyama K., Doi H., Takazoe K., Kawano H., Soejima H., Mizuno Y., Tsunoda R., Sakamoto T., Nakano T., Nakajima K., Ogawa H., Sugiyama S., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 99:1999;2858-2860.
15. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W.F., Ordovas J.M., Schaefer E.J. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women results from the Framingham Heart Study . Atherosclerosis. 154:2001;229-237.
16. Weintraub M.S., Eisenberg S., Breslow J.L. Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia. Eur J Clin Invest. 19:1989;480-485.
17. Cabezas MC, de Bruin TW, Kock LA, Kortlandt W, Van Linde-Sibenius Trip M, Jansen H, Erkelens DW. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism 1993;42:497-503.
18. Simo I.E., Yakichuk J.A., Ooi T.C. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis. 100:1993;55-64.
19. Battula S.B., Fitzsimons O., Moreno S., Owens D., Collins P., Johnson A., Tomkin G.H. Postprandial apolipoprotein B48- and B100-containing lipoproteins in type 2 diabetes do statins have a specific effect on triglyceride metabolism? Metabolism. 49:2000;1049-1054.
20. Parhofer K.G., Barrett P.H., Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 85:2000;4224-4230.
21. Sheu W.H., Jeng C.Y., Lee W.J., Lin S.Y., Pei D., Chen Y.T. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism. 50:2001;355-359.
22. Cuchel M., Schaefer E.J., Millar J.S., Jones P.J., Dolnikowski G.G., Vergani C., Lichtenstein A.H. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol. 17:1997;1910-1917.
23. Schaefer J.R., Schweer H., Ikewaki K., Stracke H., Seyberth H.J., Kaffarnik H., Maisch B., Steinmetz A. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis. 144:1999;177-184.
24. Stucchi A.F., Hennessy L.K., Vespa D.B., Weiner E.J., Osada J., Ordovas J.M., Schaefer E.J., Nicolosi R.J. Effect of corn and coconut oil-containing diets with and without cholesterol on high density lipoprotein apoprotein A-I metabolism and hepatic apoprotein A-I mRNA levels in cebus monkeys. Arterioscler Thromb Vasc Biol. 11:1991;1719-1729.
25. Velez-Carrasco W., Lichtenstein A.H., Welty F.K., Li Z., Lamon-Fava S., Dolnikowski G.G., Schaefer E.J. Dietary restriction of saturated fat and cholesterol decreases HDL Apo A-I secretion. Arterioscler Thromb Vasc Biol. 19:1999;918-924.
26. Guerin M., Lassel T.S., Le Goff W., Farnier M., Chapman M.J. Action of atorvastatin in combined hyperlipidemia preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles . Arterioscler Thromb Vasc Biol. 20:2000;189-197.
27. Ordovas J.M., Cupples L.A., Corella D., Otvos J.D., Osgood D., Martinez A., Lahoz C., Coltell O., Wilson P.W.F., Schaefer E.J. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk the Framingham study . Arterioscler Thromb Vasc Biol. 20:2000;1323-1329.
28. Miller M., Dolinar C., Cromwell W., Otvos J.D. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol. 87:2001;232-234.
29. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 88:2001;270-274.
30. Stein D.T., Devaraj S., Balis D., Adams-Huet B., Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 21:2001;2026-2031.